FindTrial
Sign In

Select imaging biomarkers for mapping pathology of myocardial fibrosis

Select imaging biomarkers for mapping pathology of myocardial fibrosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200066513
Enrollment
Unknown
Registered
2022-12-07
Start date
2022-12-10
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathy

Interventions

Ischemia cardiomyopathy group:standard guideline-directed heart failure drug +/- device therapy
Non-ischemic dilated cardiomyopathy group:standard guideline-directed heart failure drug +/- device therapy

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-85 years, no gender limit; 2. New York Heart Association Cardiac Function Scale (NYHA) II-III; 3. Echocardiographic screening during the first 4 weeks of randomization showed cardiac enlargement: LVEDD > 5.0cm (female) and > 5.5cm (male), and LVEF= 900pg/ml; Patients with renal insufficiency (glomerular filtration rate = 1200pg/ml, but all patients should be < 5000pg/ml; 7. The informed consent process is in line with regulations, and the patient himself or his legal agent signs the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with previous organic valvular disease and congenital heart disease; 2. Patients with malignant tumor; 3. Previous history of transcatheter aortic replacement (TAVI) or percutaneous coronary intervention (PCI) within 6 months; 4. Patients with serious adverse reactions and contraindications to cardiomyopathy drugs; 5. Severe infection and liver function impairment (or transaminase more than 5 times higher than the upper limit of normal value); 6. Patients who are allergic to gadolinium contrast agents; 7. Patients with magnetic metal implants; 8. Claustrophobic; 9. Pregnant or lactating patients; 10. Mental retardation or mental disorders.

Design outcomes

Primary

MeasureTime frame
all-cause death;cardiac death;readmission for heart failure;unplanned ICD or CRT implantation;unplanned heart transplant;—

Secondary

MeasureTime frame
left ventricular ejection fraction improved;6-minute walk test improved;Kansas City cardiomyopathy quality of life score improved;—

Countries

China

Contacts

Public ContactZhang Cheng

Qilu Hospital of Shandong University

zhangc@sdu.edu.cn+86 18560086628

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026